<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872013</url>
  </required_header>
  <id_info>
    <org_study_id>7991-CL-1002</org_study_id>
    <nct_id>NCT01872013</nct_id>
  </id_info>
  <brief_title>Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects</brief_title>
  <official_title>Randomized, Double-blinded, Placebo-controlled, Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics
      of ASP7991 after multiple oral administrations to non-elderly subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In each step (lowest dose, middle dose, highest dose), subjects are randomly assigned in a
      double blinded manner to receive either ASP7991 (n=9) or Placebo (n=3) and are administered
      repeatedly. Once daily, the subjects are administered ASP7991 or placebo orally 30 minutes
      after breakfast with 150 mL water for 7 days. After the each step the sponsor evaluates the
      safety in the blinded manner for deciding an escalation to the step.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>The safety of ASP7991 assessed by the incidence of adverse events, vital signs, laboratory tests, 12-lead ECGs, ECGs for QT evaluation and slit lamp examination</measure>
    <time_frame>For 96 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations unchanged drug; AUC24h, Cmax, Ctrough, tmax, t1/2, CL/F, Vz/F</measure>
    <time_frame>For 96 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary concentrations unchanged drug; Aelast, Aelast%, CLR</measure>
    <time_frame>For 96 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP7991</condition>
  <arm_group>
    <arm_group_label>low dose ASP7991</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose ASP7991</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose ASP7991</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP7991</intervention_name>
    <description>oral</description>
    <arm_group_label>low dose ASP7991</arm_group_label>
    <arm_group_label>middle dose ASP7991</arm_group_label>
    <arm_group_label>high dose ASP7991</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as judged by the investigator/sub investigator based on the results of
             physical examination obtained before study drug administration

          -  Body weight: ≥50.0 kg, &lt;80.0 kg

          -  BMI: ≥17.6, &lt;26.4

          -  Serum corrected calcium concentration: ≥9.0mg/dL, &lt;10.4 mg/dL

        Exclusion Criteria:

          -  Received any investigational drugs in other clinical or post-marketing studies within
             120 days before screening

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days,
             or blood components within 14 days before screening

          -  Received medication (including marketed drug) within 7 days before hospitalization,
             vitamin preparation including vitamin D and supplement including calcium or is
             scheduled to receive medication

          -  A deviation from normal criteria range of 12-lead ECG (QT evaluation)

          -  A deviation from the normal range in clinical laboratory tests

          -  Highly sensitive cardiac troponin T (at screening): ≥0.014 ng/mL

          -  History of drug allergies

          -  Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days
             before admission

          -  Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver
             injury)

          -  Concurrent or previous endocrine disorders (e.g., hyperthyroidism, aberration in
             growth hormone)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>June 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma concentration</keyword>
  <keyword>Urinary concentration</keyword>
  <keyword>ASP7991</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
